KN 035

Drug Profile

KN 035

Alternative Names: KN035

Latest Information Update: 30 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Alphamab
  • Developer 3D Medicines
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Immunomodulators; Programmed cell death-1 ligand-1inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 04 Apr 2018 3D Medicines plans the KN035-BTC phase III trial for Biliary-cancer(Unresectable/Inoperable, Combination therapy, Late stage disease, Metastatic disease) in China, in May 2018 (SC) (NCT03478488)
  • 15 Sep 2017 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in Japan (SC) (NCT03248843)
  • 17 Aug 2017 3D Medicines plans a phase I trial for Solid tumours (Metastatic disease, Late-stage disease) (NCT03248843)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top